What is Formation Bio?
Formation Bio operates at the intersection of biotechnology and software engineering, functioning as a tech-driven pharmaceutical entity. The company has engineered a sophisticated technology platform that optimizes critical components of clinical drug development, including trial design, patient recruitment, and data integrity. By acquiring clinical-stage assets from established pharmaceutical and biotech partners, Formation Bio applies its proprietary methodology to shorten development timelines and enhance the quality of trial outcomes. This unique business model allows the firm to unlock significant value per program, effectively bridging the gap between early-stage discovery and commercial viability in a highly regulated environment.
How much funding has Formation Bio raised?
Formation Bio has raised a total of $372M across 1 funding round:
Series D
$372M
Series D (2024): $372M with participation from Andreessen Horowitz, Emerson Collective, Sequoia Capital, and Sanofi
Key Investors in Formation Bio
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies. The company is headquartered in Menlo Park, California.
Emerson Collective
Emerson Collective is a company that invests in entrepreneurs and innovators who are driven by purpose and a sense of possibility, focusing on complex challenges in education, economic mobility, and the environment.
Sequoia Capital
Sequoia Capital is a global venture capital firm with an unparalleled track record of partnering with entrepreneurs to create market leaders, managing funds that invest across venture, growth, and late-stage opportunities.
What's next for Formation Bio?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's pipeline of clinical-stage programs and further refining its AI-driven trial optimization engine. As the pharmaceutical sector increasingly pivots toward digital transformation, Formation Bio is well-positioned to capitalize on the demand for more efficient, data-backed development pathways. The company's ability to integrate high-quality trial data with rapid execution strategies suggests a long-term growth trajectory aimed at disrupting traditional drug development paradigms. Future initiatives will likely involve deeper collaborations with global pharmaceutical entities to leverage the platform's capabilities across a broader range of therapeutic areas, ultimately driving sustainable value for stakeholders and improving patient access to life-saving therapies.
See full Formation Bio company page
